Lysophosphatidic acid (LPA) is a blood-derived bioactive lipid with numerous biological activities exerted mainly through six defined G protein-coupled receptors (LPA 1 -LPA 6 ). LPA was first identified as a vasoactive compound because it induced transient hypertension when injected intravenously in rodents. Here, we examined the molecular mechanism underlying the LPA-induced hypertensive response. The LPA-induced hypertensive response was significantly attenuated by pretreatment with a Rho kinase inhibitor, which blocks Gα 12/13 signaling. Consistent with this, the response was weakened in KO mice of LPA 4 , a Gα 12/13 -coupling LPA receptor. KO mice of another Gα 12/13 -coupling LPA receptor, LPA 6 , also showed an attenuated LPA-induced hypertensive response. However, LPA 6 Ko mice also displayed attenuated pressor responses to an adrenergic agent and abnormal blood vessel formation. Using several LPA analogs with varied affinity for each LPA receptor, we found a good correlation between the hypertensive and LPA 4 agonistic activities. Incubated mouse plasma, which contained abundant LPA, also induced a hypertensive response. Interestingly the response was completely abolished when the plasma was incubated in the presence of an ATX inhibitor. Together, these results indicate that circulating LPA produced by ATX contributes to the elevation of blood pressure through multiple LPA receptors, mainly LPA 4 .
LPA receptor agonists also serve as useful tools to evaluate the role of LPA receptor subtypes. To date, a number of compounds with structures similar to LPA have been developed in several laboratories and were shown to have distinct profiles in activating each LPA receptor 9, 10 . We previously designed and synthesized LPA analogs similar to 2-acyl-LPA (LPA with a fatty acid at the sn-2 position), so-called "T-series" compounds, in which a ring structure derived from carbohydrates is introduced as a scaffold instead of a glycerol backbone 11 . These analogs have restricted conformational flexibility due to the sugar ring structure and show unique activity for LPA [1] [2] [3] in Ca 2+ and migration assays. Some compounds, such as T13, were potent ligands for LPA 3 12 . The reactivity of the T-series compounds to LPA 4 , LPA 5 and LPA 6 have not been examined so far.
To clarify the molecular mechanism underlying the LPA-induced pressor response, we examined whether the LPA receptors cloned so far (LPA [1] [2] [3] [4] [5] [6] ) are involved in LPA-induced transient hypertension by utilizing a combination of LPA receptor KO mice and LPA analogs. Here we report that LPA 4 is the major hypertensive LPA receptor. Furthermore, we demonstrate that LPA 6 signaling is crucial for normal vasoactivity and vascular development.
Results

LPA administration induces transient hypertension in mice.
As was demonstrated in other experimental animals, administration of LPA (18:1-LPA, 1.4 mg/kg, i.v.) in ICR mice produced a weak hypotension followed by a transient hypertension that lasted for a minute (Fig. 1A) . This LPA-induced hypertension was observed regardless of mouse strain and anesthetic (data not shown). The LPA-induced hypertensive response was dose-dependent and was observed at concentrations as low as 0.014 mg/kg for oleoyl (18:1)-LPA (Fig. 1B) . The hypertensive activity of LPA was dependent on the acyl chain of LPA. Among the five LPA species tested, 18:1-LPA was the most potent in elevating blood pressure and myristoyl (14:0)-LPA was the least potent.
LPA induces a transient hypertension via the Gα 12/13 -Rho/ROCK pathway.
To reveal the intracellular signals underlying LPA-produced hypertension, we tested two GPCR signaling inhibitors (Y-27632 and PTX). We found that Y-27632, an inhibitor of a Rho kinase that is activated downstream of Gα 12/13 -Rho signaling, significantly and dose-dependently attenuated the hypertensive activity of LPA ( Fig. 2A) . In contrast, PTX, which inactivates Gα i/o proteins, had no effect. We observed that bradycardia evoked by acetylcholine i.v. administration was attenuated by PTX pretreatment (data not shown), confirming that Gα i/o proteins were inactivated. These results suggest that LPA induces a transient hypertension via putative LPA receptor(s) coupling with Gα 12/13 protein.
Unlike other GPCR assay methods, the TGFα-shedding assay, a novel assay system for detecting GPCR activation that we developed recently 13 , effectively detects Gα 12/13 signaling as well as Gα q signaling. Importantly, activation of all six LPA receptors was detectable using this assay. To evaluate possible coupling of each LPA receptor to Gα 12/13 protein, we knocked down both Gα 12 and Gα 13 by siRNA. Simultaneous knockdown of Gα 12 and Gα 13 dramatically decreased the activity of LPA 4 and LPA 6 , as was observed for knockdown of TNFα-converting enzyme (TACE) (Fig. 2B ), a crucial enzyme in the TGFα-shedding assay (Fig. 2B ). In agreement with this observation, Y-27632 significantly reduced the activities of LPA 3 , LPA 4 and LPA 6 (Fig. 2C ). In LPA 3 -expressing cells, Gα 12/13 knockdown partially inhibited the TGFα-shedding responses. These data indicate that LPA 4 and LPA 6 are the LPA receptors that mainly coupled with Gα 12/13 protein.
Attenuated LPA-induced hypertensive response in both LPA 4 -and LPA 6 -deficient mice. To identify the LPA receptors involved in the pressor effect, we tested five single LPA receptor KO mice (Lpar1, Lpar2, Lpar3, Lpar4 and Lpar6 null). Consistent with a previous report 8 , administration of LPA in Lpar1 and Lpar2 null mice induced a similar hypertensive response as was observed in wild-type mice (Fig. S1 ). Similar results were obtained with Lpar1/Lpar2 double KO mice (data not shown). The LPA-evoked pressor response was also not affected in LPA 3 -deficient mice, although the hypotensive response was attenuated ( Supplementary Fig. 1 ). These data suggest that Edg-type LPA receptors (i.e. LPA 1 , LPA 2 and LPA 3 ) are not involved in the LPA-induced hypertensive response, at least in mice. We next tested LPA 4 and LPA 6 KO mice and found that they showed an impaired pressor response to LPA (Fig. 3A) . The dose-response curve of LPA-induced hypertension is shown in Fig. 3B . LPA 4 -deficient mice showed a slightly but significantly lowered response to various LPA dosages. In www.nature.com/scientificreports www.nature.com/scientificreports/ LPA 6 -deficient mice a lower dosage of LPA (0.014 mg/kg) induced hypertensive responses similar to those in wild-type mice. However, the responses induced by higher LPA dosages were significantly lower in LPA 6 -deficient mice. To address the redundant role of LPA 4 and LPA 6 in the pressor effect of LPA, we tried to generate mice lacking both Lpar4 and Lpar6 (Lpar4/Lpar6-double null mice). However, Lpar4/Lpar6-double null pups produced by intercrossing Lpar4 +/− Lpar6 +/− female and Lpar4 +/Y Lpar6 +/− male mice were not born ( Table 1) . Although Lpar4 +/− Lpar6 −/− and Lpar4 −/Y Lpar6 +/− mice, which retained only one wild-type allele, were born fertile, the number of offspring was less than the value expected from the Mendelian ratios. Further mating experiment using Lpar4 −/− Lpar6 +/− female and Lpar4 −/Y Lpar6 +/− male also failed to generate Lpar4/Lpar6-double null mice, suggesting that complete loss of Lpar4/6 results in embryonic lethality or death after parturition, while a single remaining wild-type allele is sufficient for normal development and reproduction. We thus could not test Lpar4/Lpar6-double null mice for LPA-induced transient hypertension.
Abnormal vasoactivity and vascular development in LPA 6 -deficient mice. To examine whether
the attenuated hypertensive response induced by LPA in LPA 4 and LPA 6 -deficient mice results from their abnormal vasculature, we next examined the vasoactivity of these mice. We confirmed that both LPA 4 -and LPA 6 -deficient mice had normal blood pressure and heart rate under normal conditions ( Supplementary Fig. 2 ). LPA 4 -deficient mice showed hypertensive responses to phenylephrine similar to those observed in wild-type mice ( Fig. 4A ). LPA 4 -deficient mice also showed normal pressor responses to norepinephrine ( Fig. 4B ), indicating that their vasoactive response is not affected in LPA 4 -deficient mice despite the presence of some abnormalities in the blood vascular system of neonates as previously reported 14 . By contrast, LPA 6 -deficient mice displayed significantly lowered responses to both phenylephrine and norepinephrine ( Fig. 4C and D) , raising the possibility that they have abnormal vasculature that results in impaired vasoactivities. We thus analyzed postnatal retinal blood vessel formation in LPA 6 -deficient mice, a widely used evaluation system for physiological angiogenesis. Isolectin B4 staining, which visualizes the vascular network in the retina, revealed a decreased vascular density and branching in LPA 6 -deficient mice (Fig. 5A ). In addition, LPA 6 -deficient vessels extended few filopodia at the vascular front where most endothelial tip cells are located ( Fig. 5B ). Quantitative analyses of the retinal vessels showed 22% less EC coverage, 26% less branching points and 35% fewer tip cells number in LPA 6 -deficient mice ( Fig. 5A,B ). Accordingly, an LPA 6 signal was found to be essential for normal vasculature. Thus, we could not www.nature.com/scientificreports www.nature.com/scientificreports/ conclude that LPA 6 is involved in LPA-induced hypertension using LPA 6 -deficient mice, even though they had weakened LPA-induced pressor responses ( Fig. 3B ).
Hypertensive activity of LPA analogs, T-series compounds.
To determine the LPA receptors involved in LPA-induced hypertension, we next used a pharmacological approach using LPA analogs called T-series compounds ( Fig. 6A ). The T-series compounds were designed to identify specific active conformations of the glycerol backbone of LPA by using carbohydrates with a fixed ring structure as scaffolds 11 . We tested the hypertensive activity of six T-series compounds in mice and found that T8 was the most potent in increasing blood pressure ( Fig. 6B) , with an activity almost equal to that of LPA (18:1). T7, an LPA analog with an acyl-chain and phosphate in the opposite position to T8, also showed a pressor effect but it was less potent than T8 and LPA. In contrast, T10, T17 and T19, which are stereoisomers of T8, and T16, which is a stereoisomer of T7, were much less potent. These data indicate that putative LPA receptor(s) involved in the LPA-induced hypertensive response strictly recognize the structure of these LPA analogs.
The best vasopressor, T8, is a potent ligand for LPA 4 . Next, we evaluated the ability of the T-series compounds to activate the six LPA receptors ( Fig. 6C , Table 2 ). For LPA 1 , LPA 2 and LPA 6 , LPA was found to be the best ligand, while some T-series compounds were the best in activating LPA 3 , LPA 4 and LPA 5 . The weaker vasopressor compounds (T16, T17 and T19) were found to be potent in activating LPA 1 , LPA 3 and LPA 5 (EC 50 < 100 nM). For example, T16 and T17 were potent agonists for both LPA 1 and LPA 3 , and T19 was a potent agonist for LPA 5 , indicating that LPA 1 , LPA 3 and LPA 5 are not the LPA receptors involved in the LPA-induced hypertensive response. Interestingly, T8, the most potent vasopressor compound, was found to be a potent ligand for both LPA 4 and LPA 6 . The second most potent pressor substance, T7, activated LPA 4 , but not LPA 6 .
We then injected LPA 4 -preferred compounds (T7 and T8) into LPA 4 -deficient mice. Hypertensive activity of T8 dramatically disappeared in LPA 4 -deficient mice (Fig. 6D) , showing the involvement of LPA 4 in T8-induced hypertension. Because T8 was a potent ligand for LPA 6 (Fig. 6C ) and LPA 6 is intact in LPA 4 -deficient mice, it is reasonable to assume that LPA 6 is not the receptor involved in LPA-induced hypertension. By contrast, hypertensive activity of T7 was significantly attenuated in LPA 4 KO mice, confirming again the involvement of LPA 4 (Fig. 6D ). However, the T7-induced hypertension still remained in LPA 4 KO mice, raising the possibility that LPA target(s) other than LPA 4 are involved. Such targets do not include LPA 6 because T7 was found to be a poor agonist for LPA 6 (Fig. 6C ).
ATX-producing LPA in incubated mouse plasma induces transient hypertension. Incubated
plasma is known to contain vasoactive compounds in rats and guinea pigs 15 . LPA has been assumed to be an active component of the pressor response because abundant LPA is accumulated in incubated plasma by the action of ATX. In fact, injecting mice with incubated mouse plasma induced transient hypertension ( Fig. 7A) , as was observed with LPA ( Fig. 1A) . After 3 hr incubation, the level of plasma LPA was markedly increased to about ~10 µM, which corresponds to the LPA dosage (0.014 mg/kg) in Fig. 1B . This LPA level was significantly lowered by the ATX inhibitor (ONO-8430506) treatment (Fig. 7B) . Interestingly, the hypertensive response was not induced by incubated mouse plasma prepared in the presence of the ATX inhibitor (Fig. 7A) . These results clearly showed that LPA produced in the incubated plasma by ATX is responsible for the hypertensive activity of the plasma. 
Discussion
In this study we examined the mechanism underlying the pressor activity of LPA using several tools, including an inhibitor of an LPA-producing enzyme, five LPA receptor deficient mice and LPA analogs with different affinities for each LPA receptor. First, when mouse plasma was incubated with an ATX inhibitor, we were unable to detect the hypertensive activity of the plasma. Production of LPA in the plasma was completely suppressed by the inhibitor, showing clearly that LPA is the hypertensive substance in the incubated plasma. Among the five LPA receptor deficient mice (LPA 1-4 , and LPA 6 ), LPA 4 and LPA 6 -deficient mice had a partially but significantly attenuated LPA-induced hypertensive response (Fig. 3) . Comparison between the hypertensive and the LPA receptor agonistic activities of T-series compounds suggested that LPA 4 is the most probable hypertensive LPA receptor ( Fig. 6 and Table 2 ). Notably, the hypertensive activity of the most potent vasopressor compound T8 was almost completely suppressed in LPA 4 -deficient mice. Although we did not test LPA 5 -deficient mice, the involvement of LPA 5 could be excluded since one of the T-series compounds, T19, which was found to be a potent agonist for LPA 5 , was a poor inducer of hypertension. The present study also suggests that LPA has other target(s) than LPA 4 to induce transient hypertension, since LPA-and T7-induced hypertension was not suppressed completely in LPA 4 -deficient mice (Figs 3B and 6D ). Although LPA activates ion channels such as TRPV1 16 , this activity does not appear to be involved in hypertension because TRP channel blockers (A784168, capsazepine and AMG9810) had no effect on the hypertensive activity of LPA ( Supplementary Fig. 3 ). Because Y-27632 dramatically suppressed LPA-induced hypertensive response (Fig. 2) , GPCR-type LPA receptors other than LPA 1-6 that couple with Gα 12/13 may be involved.
Use of an ATX inhibitor clearly showed that LPA is the factor in the incubated plasma that induces transient hypertension (Fig. 1D ). Unlike incubated plasma which contains a high concentration of LPA (~ several µM level), the LPA level in the fresh plasma is quite low (Fig. 7B ). Thus, it remained unclear if endogenous LPA in the circulation controls blood pressure. The LC-MS/MS analysis revealed that the concentration of circulating LPA in healthy mice was several tens of nM (Fig. 7B) . The minimum dose of LPA to induce obvious hypertension was 0.01 mg/kg (Fig. 1B) , which corresponds with about ~ 500 nM circulating LPA. Therefore, endogenous circulating LPA seems to be slightly lower than the minimum concentration to induce hypertension. Mouse plasma contains mainly unsaturated LPA, such as 18:2-LPA, which was reported to be a potent inducer of hypertension in rat 6 . In www.nature.com/scientificreports www.nature.com/scientificreports/ the present study, unsaturated LPA, such as 18:1-LPA and 20:4-LPA, induced hypertension more efficiently than saturated LPAs (14:0, 16:0 and 18:0) in mice (Fig. 1B) . In addition, the concentration of LPA and ATX are markedly elevated in various pathological conditions. For example, unsaturated plasma LPA, such as 18:2, 20:4 and 22:6, was selectively increased in patients with acute coronary syndrome 17, 18 . Upon blood coagulation, 20:4-LPA is known to be produced in activated platelets 18 . The ATX level increases in normal pregnant women in the third trimester and to a higher extent in women facing preterm delivery 19 . Therefore, it would be quite interesting to examine whether the increased unsaturated LPA affects the blood pressure in such pathological conditions. The precise molecular mechanisms by which LPA leads to elevate blood pressure via LPA 4 remain to be elucidated. In agreement with previous studies using rats 20 , we confirmed that pretreatment by indomethacin (an inhibitor of prostanoid synthesis) and hexamethonium (a nicotinic acetylcholine receptor antagonist that acts in autonomic ganglia) had no effect on the LPA-induced hypertensive response in mice (data not shown), showing that prostanoids and the autonomic nervous system are not involved. In this study, we showed that pretreatment with Y27632, a Rho kinase (ROCK) inhibitor, significantly suppressed LPA-induced hypertensive response ( Fig. 2A) . LPA 4 is known as a Gα 12/13 -coupled GPCR according to our present data (Fig. 2B) . Recent www.nature.com/scientificreports www.nature.com/scientificreports/ studies have shown that the Rho-ROCK pathway is a novel therapeutic target in the treatment of various cardiovascular diseases, such as pulmonary hypertension and cerebral vasospasm 21, 22 . Activation of Rho downstream of G12/13 is known to elicit an actomyosin-dependent contraction of aortic smooth muscle cells in an intracellular Ca 2+ -independent manner. Thus, it is possible that an ATX/LPA/LPA 4 axis operates upstream of the Gα 13 -Rho-ROCK pathway, possibly in aortic smooth muscle cells, and is a promising drug target.
ATX-deficient mice die around embryonic day 9.5-10.5 with profound vascular defects in both yolk sac and embryo, indicating that LPA produced by ATX has a critical role in embryonic vascular development 23 . However, none of the single LPA receptor-deficient mice showed the same phenotype, although LPA 4 -deficient mice were LPA www.nature.com/scientificreports www.nature.com/scientificreports/ partially lethal due to impaired blood and lymphatic vessel formation. Thus, it remains unclear how LPA regulates embryonic vascular development. Both LPA 4 and LPA 6 couple mainly with Gα 12/13 protein (Fig. 2B) to activate Rho-ROCK signaling and act to coordinately regulate cell motile activity 24 . In this study, we showed that LPA 6 -deficient mice were viable but had obvious vascular abnormalities ( Fig. 5) , which is partially similar to the phenotype of LPA 4 -deficient mice. In contrast, we were unable to produce Lpar4/Lpar6-double null mice. It is also notable that the number of offspring carrying a single wild-type Lpar4 allele on an Lpar6-deficient background was less than expected (Table 1) . These data raise the possibility that both LPA 4 and LPA 6 generate angiogenic signaling, which is essential for embryonic vascular development and is missing in ATX-deficient mice. Interestingly only LPA 6 -deficient mice exhibited impaired pressor response to various vasopressors (Fig. 4) . Therefore, further studies are necessary to investigate the precise and differential roles of LPA 4 and LPA 6 signaling in embryonic vascular development.
In summary, we propose a novel mechanism of LPA-induced transient hypertension in which unsaturated LPA produced by ATX stimulates mainly LPA 4 and induces the hypertensive response through Gα 12/13 -Rho-ROCK signaling.
Methods
Reagents. LPA Mouse breeding. Mice (C57BL6 and ICR, male, 8 weeks) were purchased from SLC Japan. LPA 1 , LPA 2 , LPA 3 and LPA 4 knockout (KO) mice were established as described previously 14, 25, 26 . LPA 6 KO mice with a mixed 129/Sv and C57BL/6 were obtained from Deltagen (San Carlos, CA). Mice were housed under specific pathogen-free conditions in an air-conditioned room and fed standard laboratory chow ad libitum. All mice were treated in accordance with the protocol approved by the Animal Ethics Committee of the Graduate School of Pharmaceutical Sciences, Tohoku University, Japan.
Whole-mount staining and immunofluorescence staining. Immunostaining of flat-mount retinas was performed according to a previously described method 27 .
Measurement of blood pressure in mice. Male mice anesthetized with urethane (1.5 mg/kg, i.p.) were placed on a heating plate at 40 °C. Under a stereoscopic microscope, the trachea was exposed and cannulated. Subsequently, a polyethylene-tipped cannula (PE-60 tubing) was inserted into the left carotid artery to monitor arterial pressure. The arterial cannula was connected to a transducer and blood pressure signals were recorded using PowerLab4/25 (Bio Research Center, Nagoya, Japan). To analyze acute blood pressure response, a second catheter was placed in the right femoral vein to infuse agonists. Mice received a bolus injection (100 µl/time) at 5-10 min intervals. For pharmacological studies, PTX (30 µg/kg, i.v.) was dissolved in PBS and administered 24 hr and 48 hr before injection of LPA. Mice were treated with saline dilutions of Y-27632 (0.1-10 mg/kg, i.v.) 5 min before injection of LPA.
LC-MS/MS analysis.
Lipids were extracted from plasma using methanol (including 17:0-LPA as internal standard; final concentration was 100 nM) as described previously 28 and stored at −80 °C. LC-MS/MS analysis was performed according to a previously described method with minor modifications 28 . In this study, we used an LC-MS/MS system that included an Ultimate3000 HPLC and TSQ Quantiva triple quadropole mass spectrometer (Thermo Fisher Scientific). LPA analyses were performed in the multiple reactive monitoring (MRM) in negative mode 28 . LC was performed using a reverse phase column (CAPCELL PAK C18 (1.5 mm I.D. x 250 mm, particle size was 3 µm)) with a gradient elution of solvent A (5 mM ammonium formate in 95% (v/v) water, pH 4.0) and solvent B (5 mM ammonium formate in 95% (v/v) acetonitrile, pH 4.0) at 200 µL/min. Gradient conditions were as follows: hold 50% B for 0.2 min, followed by a linear gradient to 100% B over 11.8 min, hold 100% B for 5 min, return to the initial condition over 0.5 min, and maintain for 2.5 min until the end of run (total run time 20 min). AP-TGFα shedding assay. This assay was conducted according to a previously described method with several modifications 13 . To improve signal detection, HEK293 cells were transfected with Gα chimeric proteins and treated with the LPA 1-3 antagonist, Ki16425. The siRNAs were transfected into cells by using Lipofectamine RNAiMAX. We validated siRNA mediated knockdown of Gα 12 and Gα 13, previously 13 . Two days post-transfection, cells were co-transfected with mouse FLAG-LPA 1-6 , AP-TGFα and Gα chimera by using Lipofectamine2000. After 24 hr, cells were resuspended in HBSS buffer, seeded in 96 well assay plates and stimulated with ligands and 10 µM Ki16425 for 1 hr. 80 µl of conditioned media were transferred to new 96 well plates and mixed with an equal volume of p-NPP solution. AP activity was calculated by the measurement of absorbance at 405 nm with a microplate reader (Molecular Devices).
Calculations. Agonist activities in the reporter gene and shedding assays were estimated as described previously 29 . The EC 50 value and E max values were calculated by fitting a logistic equation to the data by nonlinear regression analysis. The RIA (relative intrinsic activity) values, which indicate the relative potency of an agonist to LPA, were determined. www.nature.com/scientificreports www.nature.com/scientificreports/ Statistical analysis. Unpaired Student's t-test, one-way ANOVA followed by Tukey's post hoc test and multiple comparisons t-test were used for the statistical analysis. A value of P < 0.05 was considered statistically significant.
